Free Trial

Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada logo with Medical background

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 43,100 shares, an increase of 27.9% from the May 15th total of 33,700 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 18,700 shares, the days-to-cover ratio is presently 2.3 days.

Kamada Stock Up 2.0 %

KMDA traded up $0.10 during trading on Monday, reaching $5.19. The company had a trading volume of 16,923 shares, compared to its average volume of 20,942. The stock has a market cap of $298.32 million, a P/E ratio of 22.44 and a beta of 1.06. The business has a 50 day simple moving average of $5.30 and a 200-day simple moving average of $5.65. Kamada has a 52 week low of $4.08 and a 52 week high of $6.53.

Kamada (NASDAQ:KMDA - Get Free Report) last released its earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.02). Kamada had a return on equity of 5.50% and a net margin of 8.33%. The business had revenue of $37.74 million for the quarter, compared to the consensus estimate of $38.01 million. As a group, equities research analysts expect that Kamada will post 0.26 EPS for the current fiscal year.

Institutional Trading of Kamada

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company's stock worth $7,433,000 after purchasing an additional 100,800 shares during the last quarter. Aristides Capital LLC raised its holdings in shares of Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company's stock valued at $347,000 after acquiring an additional 16,635 shares in the last quarter. Y.D. More Investments Ltd raised its holdings in shares of Kamada by 107.1% in the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company's stock valued at $177,000 after acquiring an additional 15,000 shares in the last quarter. Calton & Associates Inc. bought a new stake in shares of Kamada in the fourth quarter valued at about $111,000. Finally, EWA LLC bought a new stake in shares of Kamada in the fourth quarter valued at about $68,000. 20.38% of the stock is currently owned by institutional investors.


Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on KMDA shares. StockNews.com started coverage on shares of Kamada in a report on Tuesday, June 11th. They issued a "buy" rating for the company. HC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Kamada in a research report on Thursday, May 9th.

Read Our Latest Stock Report on Kamada

About Kamada

(Get Free Report)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

Further Reading

Should you invest $1,000 in Kamada right now?

Before you consider Kamada, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.

While Kamada currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

How to Navigate Stock Downgrades
CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines